What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1432579

Cover Image

PUBLISHER: Mordor Intelligence | PRODUCT CODE: 1432579

Asia-Pacific Autoimmune Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

PAGES: 110 Pages
DELIVERY TIME: 2-3 business days
PDF (Single User License)
USD 4750
PDF (Team License: Up to 7 Users)
USD 5250
PDF (Site License)
USD 6500
PDF (Corporate License)
USD 8750

Add to Cart

The Asia-Pacific Autoimmune Disease Diagnostics Market size is estimated at USD 1.24 billion in 2024, and is expected to reach USD 1.65 billion by 2029, growing at a CAGR of 5.96% during the forecast period (2024-2029).

Asia-Pacific Autoimmune Disease Diagnostics - Market

The treatment of autoimmune diseases requires diagnosis of the disease at the onset of disease or later. This involves clinical laboratories checking for symptoms and providing the information to physician for better treatment of the disease. All the diagnostic laboratories do not have proper equipment for carrying out immunoassays. In that case, patient will face trouble in getting the tests done and then handing over the result to the physician. To overcome these problems, recently physicians and clinical laboratories started collaborating. Since, a physician knows where proper immunoassays and immunodiagnostics can be carried out, physician collaborates with that laboratory and suggests patient to get their tests done from there and the results will directly be sent to the physician. Furthermore, with increasing usage of Electronic Medical Records (EMR), labs have access to real-time test data and metrics extracted from the Laboratory Information System (LIS) and physicians too have access to these records, which increases efficiency in diagnosis, thus boosting autoimmune diagnostics market.

APAC Autoimmune Disease Diagnostics Market Trends

Immunologic Assays Segment is Expected to Show Better Growth During the Forecast Years

Based on Diagnosis, the market is segmented into Regular Laboratory Tests, Inflammatory Markers, Immunologic Assays, Antibody Tests and Other Tests. The factors responsible for the growth of the market include cost-effectiveness, growth in the biotechnology and pharmaceutical sectors, and high sensitivity and specificity of immunoassays. When compared to conventional tests, immunologic assays have been proven to provide highly accurate results, even with very small samples.

Immunologic reactions are highly specific, as they can take place only in the presence of proper immunologic agents. This high specificity indicates high accuracy in results, enabling high sensitivity in the detection of diseases. It helps in easy detection and eliminates the need for secondary verification, which ultimately saves costs. Hence, owing to these factors, the segment is expected to show better growth in the forecast period.

APAC Autoimmune Disease Diagnostics Industry Overview

The market comprises of major market players, and these players are focusing on R&D activities and significant growth strategies. The major players into the Asia-Pacific autoimmune disease diagnostics market are Abbott Laboratories, BioMerieux, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens AG, Trinity Biotech and Thermo Fisher Scientific.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 51303



  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Public Awareness about Autoimmune Diseases
    • 4.2.2 Partnerships with Physicians and Clinical Laboratories
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Disease Type
    • 5.1.1 Systemic Autoimmune Disease
      • Rheumatoid Arthritis
      • Psoriasis
      • Systemic Lupus Erythematosus (SLE)
      • Multiple Sclerosis
      • Other Systemic Autoimmune Diseases
    • 5.1.2 Localized Autoimmune Disease
      • Inflammatory Bowel Disease
      • Type 1 Diabetes
      • Thyroid
      • Other Localized Autoimmune Diseases
  • 5.2 By Diagnosis
    • 5.2.1 Regular Laboratory Tests
    • 5.2.2 Inflammatory Markers
    • 5.2.3 Immunologic Assays
    • 5.2.4 Antibody Tests
    • 5.2.5 Other Tests
  • 5.3 Geography
    • 5.3.1 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific


  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 BioMerieux
    • 6.1.3 Bio-Rad Laboratories, Inc.
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 PerkinElmer, Inc.
    • 6.1.6 Siemens AG
    • 6.1.7 Trinity Biotech
    • 6.1.8 Thermo Fisher Scientific


Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!